Is MARK4 p.Arg625Gln (c.1874G>A) pathogenic?

MARK4 p.Arg625Gln (c.1874G>A) is classified Uncertain significance in MARK4 (ClinVar, Single submitter, 1 submitter; last evaluated 2024-10-04). AlphaMissense: ambiguous (0.4316); Very rare (popmax 0.00149%, nfe).

How common is MARK4 p.Arg625Gln (c.1874G>A) in the general population?

MARK4 p.Arg625Gln (c.1874G>A) is very rare (popmax 0.00149%, nfe) (gnomAD).

What do computational predictors say about MARK4 p.Arg625Gln (c.1874G>A)?

AlphaMissense predicts ambiguous (score 0.4316) — an in-silico prediction, not a clinical call.

MARK4 p.Arg625Gln

c.1874G>A · VCV3543408

Uncertain significance Single submitter

Classification

Uncertain significance

ClinVar

Review

Single submitter ★☆☆☆

ClinVar · 1 submitter

AlphaMissense

ambiguous

0.4316 · ACMG-weighted

gnomAD v4.1

Rare

very rare (popmax 0.00149%, nfe)

Computational evidence

Protein change
AlphaMissense	0.4316	ambiguous
REVEL	0.51	indeterminate
SaProt	LLR -9.23	tolerated
Splicing
SpliceAI	—	not assessed · no allele here is in the release
Constraint at this position
Conservation	phyloP 12	GERP 2.1, phastCons 1
Regional constraint	o/e 0.88	unconstrained · MANE · 24 kb · p 0.0023 · regional, not allelic
Overall
CADD	33.0	PHRED · no single calibrated threshold — expert panels disagree

AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.

Population frequency

gnomAD v4.1 · exomes + genomes

Grpmax group 0.00149% European (non-Finnish) · 17/1,140,556 alleles

Filtering AF 0.000908% ClinGen BA1/BS1 input FAF95, joint · FAF99 0.000742%

Overall 0.00123% 19/1,538,870 alleles · very rare exomes 18/1,387,806 · genomes 1/151,064 · joint denominator

Ancestry group	Frequency	1 in
Remaining individualsnot grpmax-eligible	0.00168%	59,430
European (non-Finnish)grpmax	0.00149%	67,092
African / African-American	0.00138%	72,574

Remaining individuals shows a higher raw frequency than the grpmax group above it. gnomAD excludes bottlenecked groups — Finnish, Ashkenazi Jewish, Amish and “Remaining individuals” — from grpmax, because founder effects make their frequencies unrepresentative for filtering. The table is sorted by frequency, so an excluded group can sit above the grpmax row.

Rarity supports pathogenicity (ACMG PM2); frequency above a disease-specific BA1/BS1 threshold argues against it. A variant frequent in one ancestry group can be near-absent in others, so a single global figure can mislead.

Variant & gene context

Gene: MARK4
Protein: p.Arg625Gln
Coding: c.1874G>A
MANE Select: NM_001199867
Type: single nucleotide variant
Location: chr19:45297951 (GRCh38)
Gene constraint: LOEUF 0.361 · pLI 1.00 (gnomAD)
Structure: AlphaFold pLDDT 67.97 · 2 PDB

Full MARK4 gene report on Sugi Atlas → Gene function, pathways, protein structure, interactions & more

Similar variants

MARK4 p.Leu226= Benign ★★ same type
MARK4 p.Thr461= Benign ★★ same type
MARK4 p.Ala168Ser Uncertain significance ★ ⚠ same type
MARK4 p.Ala389Val Uncertain significance ★ ⚠ same type
MARK4 p.Ala457Val Uncertain significance ★ ⚠ same type
MARK4 p.Ala462Val Uncertain significance ★ ⚠ same type
MARK4 p.Ala479Thr Uncertain significance ★ ⚠ same type
MARK4 p.Ala47Thr Uncertain significance ★ ⚠ same type

Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →

Cite Sugi Variant

Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/mark4-p-arg625gln (accessed [today's date]).

Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown